Healthcare Sales & Marketing Network News: epigenetic

Searching News Database: epigenetic

HSMN NewsFeed - 15 Jul 2025
Tract Bio Appoints Chris Galloway, M.D., as Chief Medical and Development Officer and Expands Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Mar 2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 19 Dec 2024
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 20 May 2024
Chroma Medicine Announces Appointment of Jenny Marlowe, Ph.D., as Chief Development Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jun 2023
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 1 Mar 2023
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 26 Sep 2022
Innocoll and DURECT Announce U.S. launch of POSIMIR(R)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 Feb 2021
DURECT Corporation Announces U.S. FDA Approval of POSIMIR(R) For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 5 Jan 2021
DURECT Corporation Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 24 Feb 2020
Dovetail Genomics Introduces New Dovetail(TM) Micro-C and HiChIP Kits
Diagnostics Product Launch

HSMN NewsFeed - 17 Jan 2020
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Oct 2019
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain
Biopharmaceuticals Drug Delivery Surgery FDA

HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 20 Jun 2019
DURECT Announces $15 Million Registered Direct Offering
Biopharmaceuticals Drug Delivery Venture Capital

HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 16 Apr 2019
Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2019
Burning Rock announces the completion of the Series C financing of RMB 850 million and strives to build an international leading tumor precision medicine brand
Diagnostics Oncology Venture Capital

HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Dec 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 14 Jun 2018
New England Biolabs(R) Launches New NEBNext(R) Single Cell/Low Input RNA Library Prep Kit for Increased Transcript Detection with Ultra-low Input Amounts
Diagnostics Product Launch

HSMN NewsFeed - 9 May 2018
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery Surgery Licensing

HSMN NewsFeed - 19 Feb 2018
Blockchain Based Medical Device from NnBU Set to Raise €15million in ICO
Devices Venture Capital

HSMN NewsFeed - 11 Jan 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 8 Jan 2018
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Jun 2017
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR(R)
Biopharmaceuticals

HSMN NewsFeed - 11 May 2017
Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jan 2017
Celgene to Acquire Delinia, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 6 May 2016
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Apr 2016
VolitionRx Announces CE Marks for Two NuQ(R) Blood Assays for Detection of Colorectal Cancer
Diagnostics Oncology Regulatory

HSMN NewsFeed - 23 Mar 2016
Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Mar 2016
Huya Bioscience International Expands Senior Management Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Jan 2016
Tensha Therapeutics To Be Acquired By Roche
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Aug 2015
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2015
RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 May 2015
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 May 2015
Gilead Sciences Acquires EpiTherapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 30 Jan 2015
Calithera Biosciences Appoints Keith Orford, M.D., Ph.D. to Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Aug 2014
Nodality Expands Senior Leadership Team, Appoints Kathleen LaPorte as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jun 2014
Agena Bioscience Announces FDA 510(k) Premarket Clearance of the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx(TM) System
Diagnostics FDA

HSMN NewsFeed - 9 Jun 2014
Rubicon Genomics Adds European Distributors Ahead Of New Product Launches
Diagnostics Distribution

HSMN NewsFeed - 26 Feb 2014
Nodality, Inc. Appoints Ralph Snyderman, M.D., to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jan 2014
Forma Therapeutics Appoints Christopher Dinsmore to Vice President, Medicinal and Computational Chemistry
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Dec 2013
Personalized Cancer Therapy, Inc. (Perthera) Launches to Provide New Hope for Fighting Advanced-Stage Cancers
Diagnostics Personalized Medicine Oncology Product Launch

HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Sep 2013
Mirati Therapeutics Appoints Isan Chen as Chief Medical and Development Officer and Adds Craig Johnson to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Aug 2013
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Jul 2013
Warp Drive Bio Appoints Co-Founder Gregory Verdine, Ph.D., to Chief Executive Officer; Expands Team with Two Key Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Nov 2012
Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Biopharmaceuticals Personalized Medicine Oncology

HSMN NewsFeed - 13 Nov 2012
Peter Wirth Named Chairman of the FORMA Therapeutics Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Sep 2012
FORMA Therapeutics Appoints Dr. Rob Sarisky to Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Jul 2012
Coferon, Inc. Announces $12 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 26 Apr 2012
Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers
Biopharmaceuticals Oncology Personalized Medicine

HSMN NewsFeed - 19 Apr 2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Apr 2012
Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Mar 2012
Constellation Pharmaceuticals Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Mar 2012
Third Rock Ventures Appoints Mark A. Goldsmith, M.D., Ph.D., as Venture Partner
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 6 Jun 2011
Constellation Pharmaceuticals Raises $15 Million in Additional Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 1 Feb 2011
Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Jan 2011
PrognosDx Announces Appointments of Dr. Garry Nolan to Board of Directors and Dr. Joseph Presti to Scientific Advisory Board
Diagnostics Oncology Personalized Medicine Personnel

HSMN NewsFeed - 22 Nov 2010
Paclitaxel Poliglumex (OPAXIO(R)) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2010
Constellation Pharmaceuticals Closes $22 Million in Series B Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 May 2010
Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Mar 2010
Epizyme Expands Leadership Team, Appointing Robert Gould, Ph.D. as CEO and Jason Rhodes as EVP and CBO
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jan 2010
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jan 2010
Constellation Pharmaceuticals Appoints Kerry K. Reinertsen, Ph.D. as Company's Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Dec 2009
Epizyme Closes $40M Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Nov 2009
Fate Therapeutics Closes $30 Million Series B Financing
Regenerative Medicine Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Oct 2009
Epizyme Closes $32 Million Series B Financing, Led by New Investor Bay City Capital
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 9 Sep 2009
EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Sep 2009
Constellation Pharmaceuticals Appoints Renowned Cancer Biologist Edward E. Harlow, Jr., Ph.D. as Company's CSO
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Aug 2009
Constellation Pharmaceuticals, Inc. Appoints Mark A. Goldsmith, M.D., Ph.D. as CEO and Closes $17 Million in Funding
Biopharmaceuticals Personnel Venture Capital

HSMN NewsFeed - 7 Aug 2009
Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors for Cancer and Rheumatoid Arthritis
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 26 Jan 2009
Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen
Diagnostics Acquisitions

HSMN NewsFeed - 24 Oct 2008
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Aug 2008
VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Jun 2008
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Jun 2008
VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Apr 2008
Constellation Pharmaceuticals Closes $32 Million in Series A Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 Feb 2008
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Feb 2008
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Feb 2008
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Feb 2008
MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Feb 2008
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Jan 2008
Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jan 2008
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Oct 2007
GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 Oct 2007
Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2007
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Aug 2007
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Biopharmaceuticals FDA Oncology

HSMN NewsFeed - 24 Aug 2007
DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Biopharmaceuticals

HSMN NewsFeed - 21 Aug 2007
MethylGene and Pharmion Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 21 Aug 2007
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Jun 2007
Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 2 Jun 2007
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Jun 2007
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2007
LabCorp(R) Licenses Gene Methylation Technology for Prostate Cancer from Veridex, LLC
Diagnostics Oncology Licensing

HSMN NewsFeed - 30 Apr 2007
World Renowned Stem Cell Researcher Dr. Rudolf Jaenisch Joins PrimeGen Biotech Scientific Advisory Board
Regenerative Medicine Personnel

HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jan 2007
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Dec 2006
New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Nov 2006
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan
Biopharmaceuticals Licensing

HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 1 Nov 2006
Pharmion Corporation Announces Enrollment of First Patient Into Vidaza(R) Patient Registry
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2006
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 May 2006
Pharmion Appoints Andrew Allen as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 May 2006
Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 5 additional stories matching:
epigenetic
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!